Talphera (NASDAQ:TLPH) Upgraded at RODMAN&RENSHAW

Talphera (NASDAQ:TLPH) was upgraded by equities research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other analysts have also issued reports on the stock. Rodman & Renshaw started coverage on shares of Talphera in a research note on Tuesday. They set a “buy” rating and a $4.00 price target on the stock. Maxim Group raised shares of Talphera to a “strong-buy” rating in a research note on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Talphera in a research report on Tuesday, January 21st.

Talphera Stock Performance

NASDAQ:TLPH opened at $0.73 on Tuesday. The stock has a market capitalization of $12.40 million, a P/E ratio of -1.06 and a beta of 0.28. Talphera has a fifty-two week low of $0.50 and a fifty-two week high of $1.61. The company has a 50 day moving average price of $0.65 and a 200 day moving average price of $0.81.

Institutional Investors Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. acquired a new position in shares of Talphera, Inc. (NASDAQ:TLPH) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera comprises about 0.4% of Rosalind Advisors Inc.’s holdings, making the stock its 25th biggest position. Rosalind Advisors Inc. owned 4.47% of Talphera as of its most recent filing with the SEC. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.